Status:
COMPLETED
Pecs II Block Versus Surgeon Infiltration for Open Subpectoral Biceps Tenodesis
Lead Sponsor:
NYU Langone Health
Conditions:
Tendonitis
Eligibility:
All Genders
18-75 years
Phase:
PHASE4
Brief Summary
A phase IV, randomized, single-blind, single-center study measuring the effects of Pecs II block with 0.25% bupivacaine versus surgeon infiltration with 0.25% bupivacaine on postoperative pain control...
Eligibility Criteria
Inclusion
- Patients between 18 and 75 years of age
- Patients undergoing shoulder arthroscopy with open subpectoral biceps tenodesis
Exclusion
- Patients younger than 18 and older than 75;
- Patients with a history of chronic pain that have used opioids for pain management for 3 months or longer;
- Patients who are allergic to oxycodone;
- Patients with diagnosed or self-reported cognitive dysfunction;
- Patients with a history of neurologic disorder that can interfere with pain sensation;
- Patients with a history of drug or recorded alcohol abuse;
- Patients who are unable to understand or follow instructions;
- Patients with severe liver disease, renal insufficiency, congestive heart failure, and/or significant heart disease;
- Patients with an allergy or contraindication to any of the medications used in the study, or patients with a contraindication to any study procedures;
- Patients with a BMI over 45;
- Any patient that the investigators feel cannot comply with all study related procedures;
- NYU Langone Health students, residents, faculty or staff members.
Key Trial Info
Start Date :
July 14 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 11 2023
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT04867369
Start Date
July 14 2021
End Date
November 11 2023
Last Update
December 13 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
NYU Langone Health
New York, New York, United States, 10016